Prime Medicine Publishes Positive Findings on PM359 for CGD

Prime Medicine, Inc. has made significant strides in genetic therapy with the publication of Phase 1/2 clinical data regarding its investigational product PM359. This announcement follows the release of findings in the prestigious New England Journal of Medicine, underscoring the company’s commitment to developing innovative treatments for rare genetic disorders.

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” details the initial outcomes from two patients enrolled in the trial. Conducted to evaluate the safety, biological activity, and preliminary efficacy of PM359, the study included both adult and pediatric participants suffering from p47phox chronic granulomatous disease (CGD).

Both subjects demonstrated rapid engraftment of neutrophils and platelets. Furthermore, the patients showed a durable restoration of NADPH oxidase activity along with early signs of clinical benefit. Importantly, no safety concerns were reported throughout the trial, marking a promising milestone for this therapy.

Presentation at ASH Annual Meeting

The findings will also be presented during a poster session at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, taking place from December 6-9, 2025, in Orlando, Florida. This event is a key gathering for hematology professionals and offers a platform for sharing the latest advancements in the field.

The results from this trial represent a first-in-human demonstration of the safety and efficacy of Prime Editing, a technology that could pave the way for targeted therapies in treating rare genetic diseases. With these findings, Prime Medicine strengthens its position as a leader in the development of one-time curative genetic therapies, specifically tailored for conditions like CGD.

As the biotechnology sector continues to evolve, the publication of these promising results is anticipated to generate interest among healthcare professionals and investors alike. The potential of PM359 as a precise therapeutic option for patients with p47phox CGD could alter treatment paradigms significantly, offering hope for those affected by this challenging condition.